| Half-life | 8 hours |
| Tmax | 2 h |
| Protein Binding | 99 % |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Usually given with Trametinib. Strong CYP3A4 inducer: many interactions. |
Severity: Moderate
Adverse Effects:
Fever, hyperglycemia, skin reactions, uveitis
Contraindications:
Severe uncontrolled cardiac disease
Precautions:
Monitor for fever (very common); manage dose interruptions as needed.